An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155
NCT ID: NCT00818480
Last Updated: 2015-09-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
10 participants
INTERVENTIONAL
2006-02-28
2012-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma
NCT00005803
A Phase I/II Study of CM355 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)
NCT05210868
Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202)
NCT00096460
Study of Repeat Intranodal Injections of Ad-ISF35
NCT00942409
Avastin Plus Rituximab for Patients With B-Cell Non-Hodgkin's Lymphoma
NCT00081861
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Each subject will be treated at the dose he/she was receiving at the completion of his/her previous phase I or phase II YM155 study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1. YM155
YM155
continuous infusion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
YM155
continuous infusion
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Lack of progression based on the most recent radiological imaging, biochemical assessments and/or physical examination
* Negative pregnancy test result (females of child-bearing potential)
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Astellas Pharma Inc
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sr. Medical Director
Role: STUDY_DIRECTOR
Astellas Pharma Global Development
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Institute for Drug Development
San Antonio, Texas, United States
South Texas Accelerated
San Antonio, Texas, United States
Huntsman Cancer Hospital
Salt Lake City, Utah, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
155-CL-101
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.